Healix Health has launched a precision cancer service in partnership with global healthcare solutions provider Further as an extension of its existing cancer care pathway.
It uses genomic testing with clinical support with the aim of delivering cost savings for employers and improving survival rates and employee outcomes.
The service is offered for a fixed annual fee per principal member, including spouse and dependents, and available to employees diagnosed with stage three or four cancer, rare cancers, cancers of unknown primary and cancers that have not responded to first-line treatment.
It is activated by the Healix clinical team who will coordinate access for eligible patients.
Genomic testing is then carried out by Further, with results reviewed by an international panel of precision medicine specialists who develop a personalised treatment plan incorporating relevant clinical trials and any hereditary considerations.
Patients will receive their results from a Further clinical case manager who will provide guidance, support clinical trial enrolment where appropriate, and offer access to a dedicated genetics pathway for cancers with hereditary features.
A Healix Health nurse will also provide ongoing support throughout the cancer journey.
Ian Talbot, CEO of Healix Health, (pictured) said: “Cancer touches every organisation. It’s no longer rare; it’s a reality for any modern workforce, with nearly a third of private healthcare claims costs now related to cancer.
“While advances in treatment have improved survival rates, they have also introduced new complexities, rising costs and greater expectations.
“This new service is going to make a big difference to the way employers tackle cancer.”
